Engineered antibodies take center stage

Human Antibodies

Volumn 10, Issue 3-4, 2001, Pages 127-142

  Huston, James S ^a   Georgeb, Andrew J T ^a  

^a Lexigen Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; MONOCLONAL ANTIBODY;

ANTIBODY COMBINING SITE; ANTIBODY ENGINEERING; ANTIBODY LIBRARY; ANTIBODY PRODUCTION; CANCER IMMUNOTHERAPY; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; GENE FUNCTION; GENE SEQUENCE; HUMAN; IMMUNOBIOLOGY; LYMPHATIC LEUKEMIA; MACROMOLECULE; MEASUREMENT; MEDICAL RESEARCH; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEOMICS; REVIEW;

EID: 0035727902     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/hab-2001-103-405     Document Type: Review

References (174)

1. Initial sequencing and analysis of the human genome
2. The sequence of the human genome
3. The story of CAMPATH-1
4. Novel folded protein domains generated by combinatorial shuffling of polypeptide segments
5. Searching for peptide ligands with an epitope library
6. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12
7. The role of structure in antibody cross-reactivity between peptides and folded proteins
8. Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage
9. Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling
10. Ligands selected from combinatorial libraries of protein A for use in affinity capture of apolipoprotein A-1M and taq DNA polymerase
11. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain
12. Staphylococcal surface display of immunoglobulin A (IgA)- and IgE-specific in vitro-selected binding proteins (affibodies) based on staphylococcus aureus protein A
13. A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries
14. Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization
15. The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies
16. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site
17. Applying phage antibodies to proteomics: Selecting single chain Fv antibodies to antigens blotted on nitrocellulose
18. Selection of tumor-specific internalizing human antibodies from phage libraries
19. Targeted gene delivery to mammalian cells by filamentous bacteriophage
20. Efficient construction of a large nonimmune phage antibody library: The production of high-affinity human single-chain antibodies to protein antigens
21. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody
22. Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7
23. Phenotypic knockout of the high-affinity Human interleukin 2 receptor by intracellular single-chain antibodies against the {alpha} subunit of the receptor
24. Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies
25. Manipulation of human minichromosomes to carry greater than megabase-sized chromosome inserts
26. Production of a diverse repertoire of human antibodies in genetically engineered mice
27. Dominant expression of a 1.3 Mb human Ig kappa locus replacing mouse light chain production
28. Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and {kappa} and {lambda} light chain yeast artificial chromosomes
29. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites
30. Memory against colon carcinoma is long-lived in the absence of antigen
31. What to do with targeted IL-2
32. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response
33. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors
34. Multiple event activation of a generic prodrug trigger by antibody catalysis
35. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides
36. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display
37. Selecting and evolving functional proteins in vitro by ribosome display
38. In vitro selection and evolution of proteins
39. Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries
40. In vitro selection and evolution of functional proteins by using ribosome display
41. Selectively-infective phage (SIP): A mechanistic dissection of a novel in vivo selection for protein-ligand interactions
42. Selectively infective phage technology
43. An in vivo library-versus-library selection of optimized protein-protein interactions
44. Anti-HER2 immunoliposomes for targeted drug delivery
45. Development of anti-p185HER2 immunoliposomes for cancer therapy
46. Design and expression of soluble CTLA-4 variable domain as a scaffold for the display of functional polypeptides
47. Development and application of cytotoxic T lymphocyte-associated antigen 4 as a protein scaffold for the generation of novel binding ligands
48. Mass spectral analysis of a protein complex using single-chain antibodies selected on a peptide target: Applications to functional genomics
49. Exploiting recombination in single bacteria to make large phage antibody libraries
50. Evolution of the display technologies
51. Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution
52. Metal binding properties of a monoclonal antibody directed toward metal-chelate complexes
53. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity
54. In vitro evolution of a T cell receptor with high affinity for peptide/MHC
55. Selection of functional T cell receptor mutants from a yeast surface-display library
56. Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency
57. Glutathione excretion in response to heterologous protein secretion in Saccharomyces cerevisiae
58. Production of antibodies in transgenic plants
59. Generation and assembly of secretory antibodies in plants
60. Feasibility of antibody production in plants for human therapeutic use
61. Purification and characterization of human growth hormone expressed and isolated from corn seed
62. Corn seed production of therapeutic proteins moves forward
63. A space-time structure determination of human CD2 reveals the CD58-binding mode
64. Identification of a proline-binding motif regulating CD2-triggered T lymphocyte activation
65. Functional glycan-free adhesion domain of human cell surface receptor CD58: Design, production and NMR studies
66. The CD58 (LFA-3) binding site is a localized and highly charged surface area on the AGFCC'C face of the human CD2 adhesion domain
67. Structure, specificity and CDR mobility of a class II restricted single-chain T-cell receptor
68. The counterreceptor binding site of human CD2 exhibits an extended surface patch with multiple conformations fluctuating with millisecond to microsecond motions
69. Composition and sequence specific resonance assignments of the heterogeneous N-linked glycan in the 13.6 kDa adhesion domain of human CD2 as determined by NMR on the intact glycoprotein
70. ScFv multimers of the anti-neuraminidase antibody NC10: Shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers
71. High avidity scFv multimers; diabodies and triabodies
72. Taking engineered anti-CEA antibodies to the clinic
73. Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer
74. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody
75. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein
76. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug
77. Generation of constitutively active recombinant caspases-3 and -6 by rearrangement of their subunits
78. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies
79. Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point
80. Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2
81. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo
82. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity
83. Improving antibody affinity by mimicking somatic hypermutation in vitro
84. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display
85. Generating improved single-chain Fv molecules for tumor targeting
86. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies
87. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu
88. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity
89. A high-affinity human antibody that targets tumoral blood vessels
90. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel
91. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis
92. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment
93. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
94. Design and use of phage display libraries for the selection of antibodies and enzymes
95. The use of phage display for the development of tumour targeting agents
96. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
97. The role of the Brambell receptor (FcRB) in liver: Protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile
98. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG
99. Metabolism of Tac (IL2Rα): Physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding
100. The protection receptor for IgG catabolism is the beta 2-microglobulin-containing neonatal intestinal transport receptor
101. Impact of antigenemia on the bioactivity of infused anti-Tac antibody: Implications for dose selection in antibody immunotherapies
102. The use of recombinant antibodies in proteomics
103. Methods for generating multivalent and bispecific antibody fragments
104. Antibody arrays for high-throughput screening of antibody-antigen interactions
105. Bypassing selection: Direct screening for antibody-antigen interactions using protein arrays
106. XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma
107. TARP: A nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus
108. High expression of a specific T-cell receptor gamma transcript in epithelial cells of the prostate
109. PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus
110. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database
111. Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis
112. Smartbombs and cloaking devices
113. RNA-peptide fusions for the in vitro selection of peptides and proteins
114. Isolation and tissue profiles of a large panel of phage antibodies binding to the human adipocyte cell surface
115. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions
116. Designer genes: Recombinant antibody fragments for biological imaging
117. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment
118. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts
119. Xenotransplantation: Will pigs fly?
120. Inhibition of expression of the Galα1-3Gal epitope on porcine cells using an intracellular single-chain antibody directed against alpha1,3galactosyltransferase
121. In vivo selection of sFv from phage display libraries
122. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: Evidence for cytotoxic mechanisms different from inhibition of protein synthesis
123. Natural and engineered cytotoxic ribonucleases: Therapeutic potential
124. Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway
125. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses
126. Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection?
127. Antibodies in human infectious disease
128. Antibody and virus: Binding and neutralization
129. Crystal structure of a neutralizing human Ig against HIV-1: A template for vaccine design
130. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization
131. A cytotoxic agent can be generated selectively at cancer sites
132. Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts
133. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library
134. Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma
135. Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis
136. Cloning the antibody response in humans with inflammatory CNS disease: Isolation of measles virus-specific antibodies from phage display libraries of a subacute sclerosing panencephalitis brain
137. Cloning the antibody response in humans with chronic inflammatory disease: Immunopanning of subacute sclerosing panencephalitis (SSPE) brain sections with antibody phage libraries prepared from SSPE brain enriches for antibody recognizing measles virus antigens in situ
138. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease